ClinVar Miner

Submissions for variant NM_000546.6(TP53):c.605G>C (p.Arg202Pro)

dbSNP: rs587778719
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV001024853 SCV001186940 uncertain significance Hereditary cancer-predisposing syndrome 2022-11-03 criteria provided, single submitter clinical testing The p.R202P variant (also known as c.605G>C), located in coding exon 5 of the TP53 gene, results from a G to C substitution at nucleotide position 605. The arginine at codon 202 is replaced by proline, an amino acid with dissimilar properties. This alteration is located in the DNA binding domain, and has been shown to be partially functional in transcriptional activation in yeast functional assays (Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul 8;100(14):8424-9). Studies conducted in human cell lines indicate this alteration is proficient at growth suppression and has no dominant negative effect (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.